Results 201 to 210 of about 1,776,183 (353)

NNMT Orchestrates Metabolic‐Epigenetic Reprogramming to Drive Macrophage‐Myofibroblast Transition in Hypertrophic Scarring

Advanced Science, EarlyView.
In macrophage‐myofibroblast transition, upregulated NNMT depletes S‐Adenosylmethionine‌ (SAM) and nicotinamide adenine dinucleotide(NAD+), thereby triggering epigenetic reprogramming via Histone H3 Lysine 27 acetylation (H3K27ac) accumulation at the promoter region of master transcription factor Prrx1.
Xiwen Dong, Weinan Guo, Yuxuan Qian, Wenyan Jin, Xiaozhen Li, Jingyuan Yang, Qingrong Ni, Shuang Wu, Fanni Li, Hua Wang, Chunying Li, Hong Cai   +11 more
wiley   +1 more source

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]

Eur J Haematol
Caserta S, Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.   +10 more
europepmc   +1 more source

A Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery

Advanced Science, EarlyView.
This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang, Chaohu Wang, Jun Fan, Zexin Chen, Haoying Yu, Yawen Bai, Tingcheng Zhang, Qianchao Zhu, Yiwen Feng, Peirong Niu, Jiaqian Chen, Liping Yang, Xueying Li, Lei Yu, Songtao Qi, Yi Liu   +15 more
wiley   +1 more source

Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide. [PDF]

Oncol Rev
Santamaria F, Roberto M, Maltese G, Nicolella F, Torchia A, Buccilli D, Di Civita MA, Giancontieri P, Marinelli D, Cirillo A, Bianco V, Verrico M, Botticelli A, Santini D.   +13 more
europepmc   +1 more source

CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target

Advanced Science, EarlyView.
CircSMEK1 is downregulated in MASH/HCC and predicts poor prognosis. It suppresses tumor progression by promoting hnRNPK ubiquitination and inhibiting the IGF2/PI3K/AKT axis, while its loss activates immunosuppressive cancer‐associated fibroblasts. Serum circSMEK1 serves as a non‐invasive diagnostic biomarker, and its restoration potently inhibits HCC ...
Peilan Guo, Xiaomeng Jia, Shenghong Wang, Xinyu Li, Yajing Liu, Lisen Lin, Zhengkun Wang, Fujun Liu, Slawomir Wolczynski, Nafis Rahman, Jie Gao, Xuguang Du, Suk‐Ying Tsang, Jiali Liu, Wei Song, Xiangdong Li   +15 more
wiley   +1 more source

Targeting Oncogenic Activity and Signalling of Mutant Receptor Tyrosine Kinase FLT3. [PDF]

Cancers (Basel)
Dobrevski B, Willems H, Lossius-Cott C, Müller JP.   +3 more
europepmc   +1 more source

Bruton’s tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy

Syeda Fadak Zahra Hujjat, Harshika Khaim Chandani, Muhammad Saad Khan, Devya Khaim Chandani, Abubakr Mahmoud   +4 more
openalex   +1 more source

Mechanisms of resistance to EGFR tyrosine kinase inhibitors

Acta Pharmaceutica Sinica B, 2015
Lihua Huang, Liwu Fu
semanticscholar   +1 more source

Tie2‐Dependent Mechanisms Influence Leptomeningeal Collateral Dynamics and Reperfusion Following Stroke

Advanced Science, EarlyView.
This work demonstrates that endothelial EphA4 limits Tie2 activation and curbs leptomeningeal collateral expansion after ischemic stroke. Pharmacological activation of Tie2 by an Ang‐1 mimetic or genetic loss of EphA4 stimulates collateral vessel growth, improves cerebral perfusion, and enhances neurological recovery.
Alexandra M. Kaloss, Caroline de Jager, Kennedie Lyles, Nathalie A. Groot, Jackie Zhu, Yu Lin, Michael Chen, Hehuang Xie, John B. Matson, Michelle H. Theus   +9 more
wiley   +1 more source

Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall? [PDF]

Cancer Drug Resist
Dong Z, Li S, Li M, Fan M, Chen K, Li A, Wang K, Zhang X.   +7 more
europepmc   +1 more source